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Summary We have examined a series of 13 benign and 27 malignant human gliomas for evidence of
molecular abnormalities of proto-oncogene and putative tumour suppressor gene loci. The results indicated
that specific molecular lesions were associated with increasing grades of malignancy. Thus, loss of genetic
material on chromosome 17 was present with approximately equal frequency in both benign and malignant
gliomas, whereas loss of loci on chromosome 10 was seen only in malignant gliomas. Only the most malignant
tumours, known as glioblastoma multiforme, had more than one molecular abnormality in the same tumour.
These findings may contribute to our understanding of glial tumour development, as well as improve the
accuracy of tumour diagnosis.
Recent attempts to define the genetic abnormalities underly-
ing tumour development have resulted in the identification of
two classes of cellular genes: oncogenes and tumour suppres-
sor genes. Functional abnormalities of these genes are
thought to result in altered cell growth control, one of the
fundamental properties of tumours.
Oncogenes act in a dominant manner; thus an abnormality
of only one proto-oncogene allele is sufficient to enhance cell
growth, even if the remaining allele is normal. Oncogenes
were first identified as the transforming genes of
tumourigenic retroviruses which were shown to be derived
from cellular proto-oncogenes acquired from the genome of
infected host cells (Bishop, 1983). Genetic alterations which
render the normal cellular proto-oncogenes capable of cel-
lular transformation include point mutations and deletions of
the coding region causing structural abnormalities of the
protein (Cooper & Whyte, 1989) and altered levels of gene
expression resulting from gene amplification and chromo-
somal translocation (Kinzler et al., 1987).
In contrast to oncogenes, certain of the tumour suppressor
(TS) genes such as the Retinoblastoma gene (RB), behave in
a recessive manner when abnormal. The abnormal genes
contribute to the development of neoplasia only if both
alleles are altered, resulting in the absence of the normal
growth inhibitory function of the gene. It is possible to
demonstrate at the molecular level that structural abnor-
malities or losses of both normal RB alleles are a prerequisite
for tumour development (Knudson, 1971; T'Ang et al.,
1988). Abnormalities of TS gene loci may arise by various
means, such as a point mutation in one allele, followed by
loss of the remaining normal allele as a result of mitotic
non-disjunction (Cavenee et al., 1983).
Abnormalities of oncogenes as well as TS genes have been
described in a wide variety of human tumours. Many of the
molecular genetic alterations described in human tumours
occur in chromosomal loci which have previously revealed
cytogenetic abnormalities; therefore known cytogenetic
abnormalities may provide clues as to which parts of the
genome require further molecular analysis (Heim & Mitel-
man, 1988; Baker et al., 1989).
Gliomas are the most common primary tumours occurring
in the human central nervous system. They are classified
histologically into astrocytomas, oligodendrogliomas and
ependymomas, each of which may be graded histologically as
low grade (grades I and II) and high grade, or malignant
(grades III, IV and glioblastoma multiforme). While a pro-
portion of the low grade astrocytomas, oligodendrogliomas
and ependymomas behave in a relatively benign manner, they
are often prone to recurrence, and tend to become increas-
ingly malignant with time. In the adult, the majority of glial
tumours are the so-called glioblastoma multiforme (GBM).
GBM is a highly malignant tumour, and may represent a
comnimn end stage of progression of less malignant glial
tumours. The median survival time for treated patients with
GBM is 11 months, a prognosis that has not changed in 35
years. In spite of numerous attempts based on cell biology,
immunocytochemistry and cytogenetics to subdivide the
gliomas into prognostically meaningful categories, we are still
no closer to understanding the fundamental biological pro-
perties which make many gliomas so refractory to therapy
(McComb & Bigner, 1984).
In an attempt to further our knowledge of the fundamental
molecular genetic lesions contributing to glioma develop-
ment, we have examined a large British cohort of benign and
malignant gliomas for evidence of loss of genetic material, an
event compatible with abnormalities of putative TS genes. In
addition, we examined the gliomas for evidence of abnor-
malities of certain proto-oncogenes. We used restriction frag-
ment length polymorphism (RFLP) analyses to search for
evidence of loss of constitutional heterozygosity of
chromosomes thought to harbour TS genes (Cavenee et al.,
1983). Polymorphic loci on chromosomes lp and 7p were
selected on the basis of previously described cytogenetic
abnormalities in gliomas (Rey et al., 1987; Bigner et al.,
1986). Additional loci on chromosomes 10 and 17 were
selected on the basis of previously described cytogenetic
studies (Rey et al., 1987; Bigner et al., 1986) and on the basis
of molecular genetic studies which used RFLP analysis
(James et al., 1988 and 1989). In addition, the integrity of the
putative TS gene p53, situated on chromosome 17p, was
assessed (Finley et al., 1989). Tumour DNA was also
examined for evidence of amplification of the epidermal
growth factor receptor (EGFR), N-myc and c-erbB-2 proto-
oncogenes. Both the EGFR and N-myc proto-oncogenes
have been shown previously to be amplified in malignant
gliomas (Libermann et al., 1985 and Garson et al., 1985,
respectively). The c-erbB-2 proto-oncogene was first
identified as the gene neu, a mutated oncogene occurring in
rat neuro-glioblastomas (Schechter et al., 1984). Subse-
quently, the human homologue, c-erbB-2, was found to be
amplified in human breast and ovarian adenocarcinomas,
where amplification was strongly linked to prognosis (Slamon
et al., 1989; Venter et al., 1987).
Our results indicate that loss of genetic material at specific
chromosomal loci is a frequent phenomenon in malignant
gliomas. Furthermore, only GBM's, which are highly malig-
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nant tumours, possess multiple molecular abnormalities in
the same tumour. Such multiple abnormalities may take the
form of loss of genetic material from more than one
chromosome, or loss of genetic material accompanied by an
oncogene abnormality. These findings may help to elucidate
the molecular mechanisms underlying tumour initiation and
progression.
Methods
Paired blood and tumour samples were obtained from 40
adult patients. Approximately half the tumour sample was
used for routine histopathological diagnosis. Blood samples
were stored at - 70°C prior to use, while the remainder of
the tumour samples were snap frozen and kept in liquid
nitrogen. DNA extraction, restriction enzyme digestion, elec-
trophoresis and Southern transfer onto nylon membranes
(Hybond-N, Amersham) were performed according to stand-
ard protocols (Cavenee et al., 1983). Probes were
radiolabelled by using the random primer method (Feinberg
& Vogelstein, 1983). Membranes were hybridised and washed
at high stringency, and autoradiography performed using
Kodak XAR film at - 70°C. In order to allow rehybridisa-
tion of the filter to a different probe, radioactivity was
removed by immersing the filter in 50% Formamide, 10 mM
Tris and 1 mM EDTA at 65°C for 30 min.
The chromosome 1, 7, 10 and 17 RFLP probes used to
detect allelic loss are listed in Table I, which indicates the
restriction enzymes used and the sizes of the alleles
generated by each enzyme. The integrity of the p53 putative
TS gene was assessed by probing Southern blots of DNA
digested with EcoRI, HindIII, and BamHI with the full-
length human p53 cDNA probe (Lamb & Crawford, 1985).
To test for oncogene amplification, DNA was digested with
EcoRI and run on 0.8% agarose gels prior to blotting. The
blots were then probed sequentially with the following
probes: p64.1 in the case of the EGFR gene (Ullrich et al.,
1984); pNB-l for the N-myc gene (Schwab et al., 1983); and
the full-length cDNA probe for the c-erbB-2 gene (Yokata et
al., 1986). After removal of radioactivity, the blots were
finally hybridised to the a-1-1 (Solomon et al., 1984), and
a-2-1 (Sykes & Solomon, 1978) collagen probes, which detect
single copy sequences on chromosomes 17 and 7, the sites of
the c-erbB-2 gene and EGFR gene respectively. Amplification
was verified by means of scanning densitometry which com-
pared the density of the autoradiographic signal produced by
each oncogene probe with that of the single copy sequences.
Results
Alterations ofgenetic material at loci which may harbour
putative tumour suppressor genes
Loss of heterozygosity at a particular locus indicates loss of
one of the parental alleles. The RB gene paradigm implies
that one allele at a locus is mutated in some way, but that
normal gene function is maintained by the presence of the
other unaltered allele. Functional abnormalities contributing
to tumour development occur only when the remaining nor-
mal allele is lost, and it is the loss of this normal allele which
is detected by studies such as the one described here
(Cavenee et al., 1983).
All the tumours were examined for loss of heterozygosity
at the loci D1OS4, DlOS1, DlOS21, PLAU, D17S28, D1S7
and D7S22. Owing to a shortage of DNA, the following
tumours were not examined at the loci indicated: Three
benign tumours at the loci DiOS5 and D17S30 and one of
these tumours was in addition not examined at the locus
D17S31; two GBM's at the loci DiOS5 and D17S31 and a
further GBM at the locus D17S30. The results of the
chromosome deletion analysis are summarised in Table II,
where the number of tumours heterozygous (and therefore
informative) for each locus is also indicated.
Loss of heterozygosity for loci on chromosome 10 was
seen in 14 out of 27 heterozygous (informative) malignant
tumours (52%), and this figure included a loss in 12 out of
19 GBM's (63%). All of the 40 tumours examined showed
heterozygosity for one or more of the chromosome 10 loci
examined. There was no evidence of loss of heterozygosity of
chromosome 10 in the 13 benign gliomas, all of which were
informative. Examples of chromosome 10 allele loss are
shown in Figure 1, panels a, b and c.
Loss of heterozygosity for loci on chromosome 17 was
observed in one out of a total of ten heterozygous benign
gliomas (10%). A similar percentage of malignant tumours
had lost a chromosome 17 allele (three out of a total of 25
heterozygous tumours, or 12%). Figure 2 shows examples of
chromosome 17 allele loss.
Table I Summary of RFLP probes to loci on chromosomes 10, 17, 1 and 7
Chromosome Allele
region HGM symbol Probe Enzyme sizes (Kb) Reference






lOq21-q23 DIOSI Dry 5-1 TaqI Al: 6.3 Pearson et al., 1987
A2: 3.6
10q21.I DIOS5 p9-12-A TaqI Al: 4.55 McDermid et al., 1987
A2: 3.8
1Oq24.33 DlOS21 CARLP118.2 BamHI A1: 7.6 Raeymaekers et al., 1988
A2: 2.3
1Oq24-qter PLAU pHUK-l BamHI Al: 7.0 Sebastio et al., 1985
A2: 1.6
17p D17S30 pYNZ22 TaqI > 10, 2-3 Kb Nakamura et al., 1987
17pl3.3 D17S28 pYNH37.3 TaqI VNTR, 5 Pearson et al., 1987
2.0-4.0 Kb
17pl3.1-11.2 D17S31 pMCT35.1 RsaI A1: 2.9 Carlson et al., 1988
A2: 2.1
lp35-p33 D1S7 pkMSl TaqI Multiple, Wong et al., 1987
2-20 Kb
7p36-qter D7S22 pAg3 TaqI Multiple, Wong et al., 1987
2-20 Kb
'HGM Symbol' refers to the chromosome allocation number for each probe as defined by the Human
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Table II Summary of chromosome deletions and EGFR amplification
Loss of heterzygositya EGFRb
Tumour type Chrom. 10 Chrom. 17 Chrom. I Chrom. 7 Amplification
Benign (low grade) (13 cases):
Oligodendroglioma 0/3 0/3 1/2 0/3 0/3
Astrocytoma 0/6 1/5 1/6 0/5 0/6
Mixed OA 0/2 0/1 0/2 0/1 0/2
Ependymoma 0/1 0/1 0/1 0/1 0/1
Choroid plexus P. 0/1 0/0 0/1 0/1 0/1
Total lost/het. (%) 0/13 1/10 (10) 2/12 (17) 0/11 Total: 0/13
Malignant (high grade) (27 cases):
Astrocytoma III 0/5 0/4 0/5 0/4 2/5
Oligo-Astro III 2/2 0/2 0/2 0/0 0/2
Glioma, undefined 0/1 0/1 0/1 0/1 0/1
Glioblastoma 12/19 3/18 0/19 0/18 3/16
Total lost/het. (%) 14/27 (52) 3/25 (12) 0/27 0/23 Total: 5/24 (19)
aNumber of tumours showing loss of heterozygosity/number of tumours informative
(heterozygous) for that probe; bNumber of tumours showing amplification (>3-5-fold)/number
of tumours examined. Chrom., chromosome number. For chromosomes 10 and 17, the result
refers to a summary of the results obtained for each chromosome using the various probes and
restrictions enzymes listed in Table I. OA and Oligo-Astro - mixed oligodendroglioma-astrocytoma.








Figure 1 Examples of allelic loss at loci on chromosome 10 in
tumour number 19, a glioblastoma multiforme. Southern analysis
of 10 fig of DNA using the restriction enzymes indicated and the
RFLP probes as designated by the HGM symbol. Three different
chromosome 10 loci are represented. Panels a, b and c demon-
strate loss ofheterozygosity in the DNA derived from the tumour
(T) when compared to normal DNA derived from the blood (B)
of patient 19. In panel a, the highest molecular weight band is an
invariant (constant) band obtained with the PLAU probe and
plays no part in forming the allelic polymorphism (Pearson et al.,
1987). Panel a, lanes 20 B and T demonstrate an example of
maintenance of heterozygosity in a tumour. The allele sizes (Al
and A2) are consistent with those described in Table I, as deter-
mined by migration of Lambda phage DNA digested with HindIII.
There was no allele loss at the chromosome 1 locus, D1S7,
in any of the malignant tumours (all of which were
heterozygous for this marker), while two out of 12 (17%)
heterozygous benign gliomas showed a loss at this locus. No
allele loss was observed at the chromosome 7 locus D7S22 in
11 heterozygous benign tumours, nor in 23 heterozygous
malignant tumours.
None of the tumours showed evidence of structural abnor-
malities of the p53 gene, using the three different restriction
enzymes described (data not shown).
Results ofstudies on the proto-oncogenes
Amplification of the EGFR was present in five out of 24
malignant gliomas examined, while none of the 13 benign
gliomas showed amplification. Only tumours displaying
21 24







Figure 2 Examples of losses of heterozygosity at loci on
chromosome 17. Southern analysis of 10 lOg of TaqI-digested
paired blood (B) and tumour (T) DNA samples probed with the
RFLP probe to the D17S30 locus. Loss of heterozygosity in
tumour DNA is seen in tumours 21 and 27. Tumour 24 shows
maintenance of heterozygosity at this locus.
greater than a. 3-5-fold increase in the amount of the EGFR
gene, as assessed by the methods used in this study, are listed
as having amplification. Two of the tumours with EGFR
amplification were malignant astrocytomas, while the remain-
ing three were GBM's (see Table II). In three of the GBM's,
the results of the EGFR analysis were not interpretable for
technical reasons. Examples of tumours possessing EGFR
amplification are shown in Figure 3.
There was no evidence in any of the tumours of
amplification of the N-myc or of the c-erbB-2 proto-
oncogenes (data not shown).
Only GBM's possessed multiple molecular abnormalities
within the same tumour. Three GBM's had a deletion of loci
on chromosome 10 as well as amplification of the EGFR
gene; whilst a further GBM had deletions of loci on both
chromosomes 10 and 17.
Discussion
Two major findings emerge from the present study. Firstly,
allelic loss of putative TS loci on chromosome 17 were
present in both benign and malignant gliomas, whilst loss of
loci on chromosome 10 were seen only in malignant gliomas,
including GBM's. Secondly, only GBM's showed evidence of
loss of loci on more than one chromosome, or both loss of a
locus as well as an associated abnormality of an oncogene.
Because of the limitations of the RFLP analysis technique
used in this study, the successful demonstration of an allelic
a 19 20
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Figure 3 Amplification of the EGFR gene in malignant gliomas.
Southern analysis of 101tg of EcoRI-digested DNA obtained
from blood lymphocytes of a healthy volunteer (lane N) and
from glioma biopsies, numbers 14 to 16 and 32 to 34. The
presence of-amplification was assessed by comparing the signal
obtained with the p64.1 EGFR probe (panel A), with that
obtained by the a-2-1 (panel B) and a-l-l (panel c) collagen
probes. Tumours 15 and 33 show amplification of the EGFR
gene. Kbp =molecular weight as assessed by migration of
Lambda phage DNA digested with HindIII.
loss in a tumour homogenate implies that the majority of the
cells in the tumour are members of a single clone possessing
that particular genetic abnormality. Loss of an allele
indicates loss of part of a chromosome or the entire
chromosome. Deletion of material from a specific chromo-
some in a significant proportion of tumours of a particular
histological type is considered to be an indication of a non-
random event which may have contributed to the growth of
the tumour cells (James et al., 1988).
Loss of heterozygosity at one or more of the three loci on
chromosome 17 was observed in 10% of informative benign
astrocytomas. In the case of malignant tumours, three
tumours out of 25 constitutionally heterozygous cases (i.e.
12%) showed loss of an allele. Thus the incidence of deletion
of loci on chromosome 17 was similar in both benign and
malignant tumours. In contrast, loss of heterozygosity of loci
on chromosome 10 was not seen in any of 13 benign consti-
tutionally heterozygous tumours, whereas 14 out of 27 malig-
nant tumours (52%) showed an abnormality. These results
concur favourably with the data obtained in studies on non-
British patient cohorts, and are consistent with the
hypothesis that chromosome 17p loss may represent an event
in the development of benign glial tumours, while loss of
chromosome 10 alleles is associated with a transition to a
malignant phenotype (James et al., 1988; James et al., 1989;
El-Azouzi et al., 1989; and Fujimoto et al., 1989).
This study failed to identify loss of an allele at the
chromosome 7p locus in the tumours. Similarly, the failure of
any of the malignant tumours to display loss of the
chromosome 1 allele examined suggests that this particular
molecular event is not detectable in the majority of the cells
in these malignant tumours. Two of the benign tumours did
show allelic loss at the chromosome 1 locus, and further
studies are needed to determine whether these losses are
indicative of a specific and reproducible molecular event
which contributes to the development of benign gliomas. The
techniques used in the present study may not reveal loss of
heterozygosity in a minority of tumour cells, and as many
malignant gliomas show pronounced microscopic hetero-
geneity, it is possible that a subset of the cells making up
certain malignant gliomas also have loss of alleles on
chromosome 1.
The p53 gene, situated on chromosome 17p, is believed to
function normally as a TS gene, and may therefore represent
a specific target of abnormalities of chromosome 17 seen
here. We therefore examined the p53 gene directly by probing
Southern blots with the full-length p53 cDNA probe. This
approach failed to reveal any abnormalities of the p53 gene,
although it has proved successful in the past in demon-
strating p53 abnormalities in osteosarcomas (Masuda et al.,
1987). It is possible that direct sequencing of the amplified
gene product may reveal more subtle abnormalities such as
point mutations, similar to those found in colorectal car-
cinomas (Baker et al., 1989).
Only glioblastomas, the most malignant of the gliomas,
revealed multiple molecular abnormalities within the same
tumour. Thus, three GBM's had a deletion of loci on
chromosome 10q, as well as amplification of the EGFR gene.
A further GBM had deletions of loci on both chromosome 10
and 17. The presence in the same cell of two or more
oncogenes from different functional groups may have a
cumulative effect, resulting in the evolution of a more malig-
nant phenotype (Land et al., 1983). Similarly, abnormalities
of both oncogenes and TS genes occurring in the same cell
may result in increased tumourigenicity (Weinberg, 1989). It
is therefore possible that the presence in three of the GBM's
of loss of putative TS gene loci as well as amplification of the
EGFR, a membrane-bound oncogene, may be associated in
some way with the development of the highly malignant
GBM phenotype. Similarly, as observed in one additional
GBM, the association of loss of genetic material from more
than one chromosome, which might be compatible with
abnormalities of multiple TS loci, may also have a
cumulative effect resulting in increased tumourigenicity.
Abnormalities of several different oncogenes and/or TS genes
may ultimately lead to the same malignant phenotypic end
point. Further studies are necessary to establish whether this
is the case.
On the basis of the data presented here, it is possible to
associate certain molecular abnormalities with gliomas of
increasing grades of malignancy. Thus, benign gliomas
(grades I and II) may possess abnormalities of putative TS
loci on chromosome 17p, as well as on chromosome 1. The
development of malignancy (histological grade III) is fre-
quently associated with loss of a locus on chromosome 10, or
of the whole chromosome. The presence of an associated
abnormality of an oncogene such as amplification of the
EGFR gene, is associated with the development of an even
more malignant phenotype, the GBM's. The association of
stepwise genetic lesions with increasing grades of glial malig-
nancy may provide the basis for a testable model of the
molecular events underlying glial tumour progression, similar
to the model proposed for colorectal tumours (Vogelstein et
al., 1988).
The association of specific molecular genetic lesions with
differing grades of malignancy may also prove of value in
tumour diagnosis. The choice of treatment given to a partic-
ular patient is often based on the histological grading of the
tumour. Given the small size of many of the biopsies submit-
ted for diagnosis, coupled with the extreme morphologic
heterogeneity present in some gliomas, it may be impossible
to identify a minority of malignant cells in an otherwise
benign tumour. However, this small proportion of malignant
cells may represent a subclone which may ultimately deter-
mine the biological behaviour of the glioma. Such malignant
subclones may be identifiable in the future by the use of gene
amplification techniques, coupled with knowledge of the
molecular genetic lesions associated with specific stages of
glial tumour progression.
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Note added in proof.
Further analysis on the same cohort of tumours revealed a deletion
of exons 18-24 of the Retinoblastoma gene (RB) in one of the
GBM's. Three further GBM's showed loss of heterozygosity at an
RFLP locus situated within the RB gene. Thus, 44% of the
heterozygous GBM's showed deletions within the RB gene. The RB
gene deletions were not present in gliomas of lower malignancy
grade. Deletions within the RB gene may therefore constitute a
further example of a sequential molecular abnormality confined to a
specific stage of human glioma evolution (Venter, et al., 1991).
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